PIOS (Patras Immunotherapy Score) Score Is Associated with Best Overall Response, Progression-Free Survival, and Post-Immunotherapy Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) Treated with Anti-Program Cell Death-1 (PD-1) Inhibitors

Immunotherapy with immune checkpoint inhibitors (ICIs) has changed the therapeutic management of advanced non-small cell lung cancer (aNSCLC) over the last decade. However, there is an unmet need for clinically useful biomarkers in this patient subgroup. The aim of this study was to combine baseline...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cancers (Basel)
Auteurs principaux: Dimitrakopoulos, Foteinos-Ioannis, Nikolakopoulos, Achilleas, Kottorou, Anastasia, Kalofonou, Fotini, Liolis, Elias, Frantzi, Theodora, Pyrousis, Ioannis, Koutras, Angelos, Makatsoris, Thomas, Kalofonos, Haralabos
Format: Artigo
Langue:Inglês
Publié: MDPI 2020
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7280986/
https://ncbi.nlm.nih.gov/pubmed/32429368
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12051257
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires